» Articles » PMID: 8299720

Recombinant Bone Morphogenetic Protein-4, Transforming Growth Factor-beta 1, and Activin A Enhance the Cartilage Phenotype of Articular Chondrocytes in Vitro

Overview
Journal Exp Cell Res
Specialty Cell Biology
Date 1994 Feb 1
PMID 8299720
Citations 21
Authors
Affiliations
Soon will be listed here.
Abstract

Bone morphogenetic protein-4 (BMP-4) is a member of the transforming growth factor-beta (TGF-beta) supergene family and is characterized by its ability to induce singly de novo cartilage and bone in vivo. The influence of recombinant bone morphogenetic protein-4 and some related members, TGF-beta 1, activin A, and inhibin A, on articular chondrocyte metabolism in the presence and absence of extracellular matrix has been examined. BMP-4 and TGF-beta 1 stimulated [35S]-sulfate incorporation in a dose-dependent manner in short-term monolayer, micromass, and explant cultures. Activin A showed a slight but significant stimulation of proteoglycan synthesis while inhibin A decreased metabolic activity. The effects observed were most pronounced in the explant culture system. Although the relative influence of the growth factors was less apparent in chondrocytes isolated from adult cartilage, the qualitative responses were similar with cells obtained from young animals. The maintenance and enhancement of the cartilage phenotype was further investigated by Northern blot analysis. BMP-4 and TGF-beta 1 increased the levels of expression of type II collagen and proteoglycan aggrecan in short-term cultures, while activin A and inhibin A did not affect these parameters significantly when compared to serum-free control cultures. Binding experiments with 125I-BMP-4, revealed the presence of specific, high-affinity binding sites with an apparent dissociation constant of 110 pM and about 6000 receptors per cell. Chemical cross-linking showed the presence of three components (apparent size 200, 90, and 70 kDa), demonstrating the presence of functional receptors for BMP-4 on primary articular chondrocytes.

Citing Articles

Advanced nanoparticles in osteoarthritis treatment.

Liang Q, Cheng Z, Qin L Biomater Transl. 2024; 5(2):95-113.

PMID: 39351157 PMC: 11438607. DOI: 10.12336/biomatertransl.2024.02.002.


Growth factors that drive aggrecan synthesis in healthy articular cartilage. Role for transforming growth factor-β?.

van der Kraan P, van Caam A, Blaney Davidson E, van den Bosch M, van de Loo F Osteoarthr Cartil Open. 2024; 6(2):100459.

PMID: 38486843 PMC: 10938168. DOI: 10.1016/j.ocarto.2024.100459.


Signalling interaction between β-catenin and other signalling molecules during osteoarthritis development.

Feng J, Zhang Q, Pu F, Zhu Z, Lu K, Lu W Cell Prolif. 2024; 57(6):e13600.

PMID: 38199244 PMC: 11150147. DOI: 10.1111/cpr.13600.


Osteoarthritis: pathogenic signaling pathways and therapeutic targets.

Yao Q, Wu X, Tao C, Gong W, Chen M, Qu M Signal Transduct Target Ther. 2023; 8(1):56.

PMID: 36737426 PMC: 9898571. DOI: 10.1038/s41392-023-01330-w.


Strategies to Modulate the Redifferentiation of Chondrocytes.

Hu X, Zhang W, Li X, Zhong D, Li Y, Li J Front Bioeng Biotechnol. 2021; 9:764193.

PMID: 34881234 PMC: 8645990. DOI: 10.3389/fbioe.2021.764193.